HUTCHMED (CHINA) LIMITED

(HCM)
  Rapport
Vertraagde tijd London Stock Exchange  -  17:35 27-06-2022
215.00 GBX   +1.42%
01/06HUTCHMED krijgt goedkeuring van de overheid voor het gebruik van het oncologisch geneesmiddel Tazverik in de Chinese pilootzone voor medisch toerisme Hainan
MT
01/06HUTCHMED kondigt aan dat TAZVERIK(R) goedgekeurd is voor gebruik in Hainan Pilot Zone in China
CI
17/05Aziatische ADR's stijgen in de dinsdaghandel
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société HUTCHMED (CHINA) LIMITED
13:55HUTCHMED CHINA : to Announce 2022 Half-Year Financial Results - Form 6-K
PU
10:30HUTCHMED to Announce 2022 Half-Year Financial Results
AQ
01/06HUTCHMED CHINA : Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China - F..
PU
24/05HUTCHMED CHINA : ​ - Form 6-K
PU
16/05Appointment of Non–Executive Director
AQ
02/05HUTCHMED CHINA : INSIDE INFORMATION - Form 6-K
PU
27/04HUTCHMED CHINA : Annual General Meeting held on April 27, 2022 – Poll Results - Form..
PU
21/04HUTCHMED CHINA : Vesting of awards under the Long Term Incentive Plan - Form 6-K
PU
31/03HUTCHMED CHINA : Update on Status under Holding Foreign Companies Accountable Act - Form 6..
PU
31/03Update on Status under Holding Foreign Companies Accountable Act
AQ
23/03HUTCHMED CHINA : Annual Report and Notice of Annual General Meeting - Form 6-K
PU
11/03HUTCHMED CHINA : Update on Status under Holding Foreign Companies Accountable Act - Form 6..
PU
09/03HUTCHMED CHINA : Vesting of awards under the Long Term Incentive Plan - Form 6-K
PU
07/03HUTCHMED CHINA : Receives a US$15 million Milestone from AstraZeneca for Initiating Start-..
PU
07/03HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Ac..
AQ
03/03HUTCHMED CHINA : Reports 2021 Full Year Results and Provides Business Updates - Form 6-K
PU
03/03HUTCHMED CHINA : ​ - Form 6-K
PU
03/03HUTCHMED announces retirement of CEO and appointment of new CEO
AQ
03/03HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
AQ
01/03HUTCHMED CHINA : Receives Approval to Commercialize ELUNATE® in Macau - Form 6-K
PU
01/03HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau
AQ
07/02HUTCHMED CHINA : to Announce 2021 Final Results - Form 6-K
PU
07/02HUTCHMED to Announce 2021 Final Results
AQ
04/02HUTCHMED CHINA : Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy ..
PU
04/02HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or To..
AQ
20/01HUTCHMED CHINA : Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant..
PU
20/01HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Soli..
AQ
19/01HUTCHMED CHINA : Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Ga..
PU
19/01HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastroi..
AQ
18/01TR-1 : Standard form for notification of major holdings - Form 6-K
PU
12/01HUTCHMED CHINA : Receives Break­through Therapy Designation in China for HMPL-523 for Trea..
PU
10/01HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..
PU
10/01HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
AQ
03/01HUTCHMED CHINA : Blocklisting Six Monthly Return - Form 6-K
PU
2021HUTCHMED CHINA : Included in FTSE Russell Indexes - Form 6-K
PU
2021HUTCHMED Included in FTSE Russell Indexes
AQ
2021HUTCHMED CHINA : ​ - Form 6-K
PU
2021HUTCHMED CHINA : Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meetin..
PU
2021HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting
AQ
2021HUTCHMED CHINA : Highlights Surufatinib and Toripalimab Combination Clinical Data being Pr..
PU
2021HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Present..
AQ
2021HUTCHMED CHINA : Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fru..
PU
2021HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquint..
AQ
2021HUTCHMED CHINA : Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Add..
PU
2021HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition..
AQ
2021HUTCHMED CHINA : and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO®..
PU
2021HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Comb..
AQ
2021Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now avail..
AQ
2021International companies to host live webcasts at Deutsche Bank's Depositary Receipts Vi..
AQ
2021HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeti..
PU
2021HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeti..
AQ
2021HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..
PU
2021HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..
AQ
2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..
PU
2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..
AQ
2021HUTCHMED CHINA : Grant of Awards under Long Term Incentive Plan - Form 6-K
PU
2021HUTCHMED CHINA : Announces Closing of Divestment of Non-Core OTC Joint Venture (Form 6-K)
PU
2021HUTCHMED CHINA : Announces Closing of Divestment of Non-Core OTC Joint Venture
AQ
2021HUTCHMED CHINA : Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with T..
PU
2021HUTCHMED CHINA : Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with T..
AQ
2021HUTCHMED CHINA : — Following surufatinib launch in China in January 2021; NDA accept..
PU
2021HUTCHMED CHINA : Initiates a Japan Bridging Study to Support Surufatinib Registration for ..
AQ
2021HUTCHMED CHINA : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-..
PU
2021HUTCHMED CHINA : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-..
AQ
2021HUTCHMED CHINA : — Follows important findings from the SAVANNAH study of this combin..
PU
2021HUTCHMED CHINA : Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-..
PU
2021HUTCHMED CHINA : Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtua..
AQ
2021HUTCHMED CHINA : Grant of Share Options under Share Option Scheme and Awards under Long Te..
PU
2021HUTCHMED CHINA : Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tisleli..
PU
2021HUTCHMED CHINA : Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tisleli..
AQ
2021HUTCHMED CHINA : Selected as Constituent of Certain Hang Seng Indexes (Form 6-K)
PU
2021HUTCHMED CHINA : Selected as Constituent of Certain Hang Seng Indexes
AQ
2021EPIZYME : and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVE..
AQ
2021HUTCHMED CHINA : Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Comm..
BU
2021HUTCHMED CHINA : Reports 2021 Interim Results and Provides Business Updates (Form 6-K)
PU
1  2Volgende
Volgende evenement op HUTCHMED (CHINA) LIMITED